1. Introduction {#sec1-metabolites-09-00199}
===============

Metabolites are low-molecular-weight compounds, present in biological matrices as systemic outcomes of various metabolic cascades \[[@B1-metabolites-09-00199]\]. In other words, metabolites reflect the chemical regulations and transformations that occur within living organisms \[[@B2-metabolites-09-00199],[@B3-metabolites-09-00199]\]. Metabolomics, the last member of the "omics" family, aims to identify and quantify metabolites such as amino acids, carbohydrates, and steroids existing in biological systems \[[@B4-metabolites-09-00199]\]. Currently, untargeted metabolomics and targeted metabolomics are the two main approaches of metabolic phenotyping research \[[@B5-metabolites-09-00199]\]. The untargeted approach aims to identify various metabolites, while the targeted approach focuses on a smaller number of metabolites under a specific condition or a metabolic pathway of interest \[[@B6-metabolites-09-00199]\]. A large body of evidence has suggested that metabolic profiling could be a beneficial approach for the assessment and management of human diseases \[[@B7-metabolites-09-00199]\]. More importantly, the flexibility and profound applicability of metabolomics, together with other omics, may assist with the development of translational and precision medicine \[[@B8-metabolites-09-00199],[@B9-metabolites-09-00199],[@B10-metabolites-09-00199]\].

Lipidomics is a sub-field of metabolomics that specifically targets lipids. It has many unique characteristics regarding the technical aspect \[[@B11-metabolites-09-00199]\]. Thus, lipids are usually analyzed separately from other more hydrophilic metabolites. Lipidomics has a wide range of applications, especially in the field of biomedical research \[[@B12-metabolites-09-00199]\]. Indeed, it could be implemented as a part of a mechanistic study or be applied for clinical biomarker discovery \[[@B13-metabolites-09-00199],[@B14-metabolites-09-00199]\]. Among characterized metabolites, steroids belong to a family of molecules that play an essential role in cell structure formation and signal transduction \[[@B15-metabolites-09-00199]\]. In living organisms, steroids are mainly synthesized in the gonads, placenta, and adrenal cortex \[[@B6-metabolites-09-00199]\]. A disturbance in steroid homeostasis usually results in various disorders \[[@B16-metabolites-09-00199],[@B17-metabolites-09-00199]\]. Recently, the roles of steroids in cancer have gained much attention, especially in endocrine and reproductive cancers. Indeed, there has been intensive research focusing on the dysregulations of steroids in adrenal cancer, breast cancer, and prostate cancer, to name a few \[[@B18-metabolites-09-00199],[@B19-metabolites-09-00199],[@B20-metabolites-09-00199]\]. Abnormal levels of steroid could be quantitatively measured to assist in the diagnosis and management of malignancies in clinical practice. For instance, the difference in steroid levels in biofluids and tissues between malignant and non-malignant conditions could be utilized to develop novel biomarkers for cancer risk prediction, diagnosis, and management \[[@B21-metabolites-09-00199],[@B22-metabolites-09-00199],[@B23-metabolites-09-00199]\].

Although the importance of steroid profiling has been demonstrated in cancer screening, diagnosis, prognosis, and management, comprehensive review and appraisal of the methodology are yet to be undertaken \[[@B24-metabolites-09-00199],[@B25-metabolites-09-00199]\]. Additionally, possible pitfalls of analytical aspects in high-throughput steroid profiling have not been thoroughly described. These issues may hamper the translation of discovered biomarkers into clinical practice. Thus, this study was set out to systematically analyze and examine the latest research on the clinical functions of steroidomics in cancer. Moreover, current technical limitations, suboptimal methodological approaches, and the role of data analysis in steroid characterization were thoroughly reviewed.

2. Results {#sec2-metabolites-09-00199}
==========

2.1. Synthesis of Literature and Search Strategies {#sec2dot1-metabolites-09-00199}
--------------------------------------------------

After the literature search, we retrieved 1315, 1019, 228, 529, 1107, and 27 articles from PubMed, Scopus, Embase, Web of Science Core Collection, Virtual Health Library (VHL), and Cochrane Controlled Register of Trials (CENTRAL), respectively. Subsequently, 1230 duplicate articles were removed, leaving 2995 references, which were screened for their title and abstract. After independent screening by at least two authors, 2920 papers were excluded in this step. In detail, 890, 821, 610, 390, 103, 102, two, and two papers were excluded for the following reasons: in vitro study, in vivo study, review article, non-human study, case report, no suitable platform, conference abstract, and proposal, respectively. Finally, the full-text of 75 eligible articles was carefully perused. While evaluating the articles, we found 15 additional papers by manual search. Finally, only 45 papers, 30 from the systematic search and 15 from the manual search, were suitable for data extraction. An overview of our study design and workflow of the record screening and assessment is given in [Figure 1](#metabolites-09-00199-f001){ref-type="fig"}.

2.2. Characteristics of the Included Studies {#sec2dot2-metabolites-09-00199}
--------------------------------------------

[Table 1](#metabolites-09-00199-t001){ref-type="table"} shows an overview of the population characteristics of the 45 included studies. Prostate cancer (PC) and adrenal cancer (AC) were the two most investigated diseases related to steroids, followed by breast cancer (BC) and endometrial cancer (EC). The roles of steroids were also explored in other types of cancer, such as ovarian cancer, esophageal and gastric cancer (E/GC), and liver cancer (LC). Pathological confirmation was primarily performed as the reference diagnostic method to confirm stages of cancer in 22 studies. Sample sizes in the cancer groups ranged from three to 1298 cases, while sample sizes of the control groups ranged from seven to 1524 cases, with one additional study recruiting 1776 patients in total. Among these studies, 33 studies had healthy individuals in the control group. It is worth noting that 18 studies utilized one or a mixture of non-cancerous conditions as control groups, such as a benign mass. In terms of study purpose, risk prediction (*n* = 18) and diagnosis (*n* = 16) were the primary outcomes among the studies. For cancer risk prediction, the association between estrogens and estrogen metabolites and cancer risk was the most reported. Regarding diagnosis purpose, adrenal cancer-related studies were the most predominant compared to other malignancies. Although there were many papers (*n* = 16) reporting diagnostic aspects of cancer, 13 of these studies either lacked information on stages of cancer or included late-stage (stage III-IV) cancers in the cohorts. Moreover, only approximately half of the included studies (*n* = 22) reported the follow-up period in their study. [Figure S1](#app1-metabolites-09-00199){ref-type="app"} shows a descriptive summary of the included studies.

2.3. Sample Preparation and Analytical Procedures of the Included Studies {#sec2dot3-metabolites-09-00199}
-------------------------------------------------------------------------

[Figure 2](#metabolites-09-00199-f002){ref-type="fig"} and [Supplementary Table S1](#app1-metabolites-09-00199){ref-type="app"} summarize the sample characteristics and analytical procedure characteristics. Among 45 included studies there are 34 studies conducting a targeted steroid approach and the other studies (*n* = 11) reported steroid metabolites as part of the metabolite profiling results. Regarding the sample type, serum (*n* = 22), urine (*n* = 16), and plasma (*n* = 8) were the three types of biospecimen used in studies concerning steroid biomarkers. One study was conducted using both urine and serum samples. After collection, samples were commonly stored at −80 °C (*n* = 17) and −70 °C (*n* = 13), and about one-fifth of the studies stored samples at --20 °C. The liquid chromatography-mass spectrometry (LC-MS, *n* = 30) and gas chromatography-mass spectrometry (GC-MS, *n* = 20) were the most employed analytical platforms. Notably, eight studies employed both platforms; among them, three studies used targeted steroidomics, while the remaining five were untargeted metabolomics. Additionally, only four studies used other methods (open column, liquid chromatography with ultraviolet detection, liquid chromatography with diode array detection, and gas chromatography with flame ionization detector) for investigating the metabolites. The use of internal standard was a common practice and was observed in 32 studies, while 29 studies included quality control samples for the analytical validation. Authentic standards (*n* = 27) were the most frequently used method for steroid identification.

2.4. Steroids and the Prevention, Assessment, and Management of Cancer Patients {#sec2dot4-metabolites-09-00199}
-------------------------------------------------------------------------------

Most of the included studies in our analysis focused on steroid analysis to evaluate the associated metabolic processes. For instance, alterations in estrogen and androgen metabolism were associated with endocrine-related cancers, including prostate, breast, endometrial, and ovarian cancer \[[@B38-metabolites-09-00199],[@B41-metabolites-09-00199],[@B43-metabolites-09-00199],[@B47-metabolites-09-00199],[@B51-metabolites-09-00199]\]. Furthermore, esophagus and gastric cancer were also reported to have associations with commonly reported steroids such as dehydroepiandrosterone (DHEA), testosterone, and estradiol \[[@B39-metabolites-09-00199],[@B40-metabolites-09-00199]\]. In a significant number of risk prediction studies, samples were withdrawn from a defined cohort \[[@B39-metabolites-09-00199],[@B42-metabolites-09-00199],[@B44-metabolites-09-00199],[@B49-metabolites-09-00199]\]. Additionally, 10 included studies suggested the association between estrogen metabolism and cancer risk development.

Regarding the diagnostic aspect, most of the studies explored the alterations between the cancer patients and other groups, usually healthy controls. Of these, adrenocortical carcinoma (ACC) was mainly reported and usually distinguished from adrenocortical adenoma (ACA). Few studies reported steroid panels to classify cancer status and other conditions. For instance, Schweitzer and colleagues reported a group of steroid compounds predicting ACC, ACA, and healthy group with the high area under the curve (AUC) \[[@B26-metabolites-09-00199]\]. Since ACC is a rare disease, most ACC-related studies were conducted with small sample sizes compared to the other studies. It should, however, be noted that a considerable number of this type of research did not present follow-up reports, an important characteristic of diagnostic studies. It is also worth noting that there were two studies that characterized steroids on four types of cancer and suggested a panel of four steroids, which helped differentiate healthy and cancer samples with a sensitivity of 0.81 and a specificity of 0.74 \[[@B33-metabolites-09-00199]\] and another with a sensitivity of 1.00 and a specificity of 0.89 \[[@B23-metabolites-09-00199]\]. Primarily, the steroid level was suggested to have an essential role in the prognosis and therapy monitoring of cancers, such as prostate, breast, and liver cancer. However, it seemed that, except for cancer risk prediction and diagnosis, steroid profiling had not been well-studied in prognosis and therapy monitoring. Hence, there was no steroid panel suggested for these purposes. Most of the studies primarily monitored steroids associated with increased survival time or therapeutic efficacy. For instance, unconjugated estradiol was correlated with breast cancer and lower estriol levels correlated with higher recurrence rate and lower overall survival in EC patients \[[@B50-metabolites-09-00199],[@B54-metabolites-09-00199]\]. The detailed results of each study are shown in [Table S2](#app1-metabolites-09-00199){ref-type="app"}. [Table 2](#metabolites-09-00199-t002){ref-type="table"} summarizes the potential steroid biomarkers in cancer, which show a significant alteration in cancer compared to other groups.

2.5. Assessment of Reporting Methodology Quality {#sec2dot5-metabolites-09-00199}
------------------------------------------------

Thirty-nine out of 45 studies reported at least eight of the 16 quality assessment items. The six remaining studies reported at least six quality assessment items. Among these items, sample information, sample preparation, and reference standards were the most commonly reported, while 28 studies mentioned the inclusion and exclusion criteria in their studies. The detailed information is presented in [Table S3](#app1-metabolites-09-00199){ref-type="app"}.

2.6. Steroid Profiling Pathway Analysis and Network Analysis {#sec2dot6-metabolites-09-00199}
------------------------------------------------------------

We recorded 105 steroids throughout the included studies and 66 out of 105 steroids had the HMDB ID. Among 105 steroids, 55 steroids were reported as significantly dysregulated in cancers in at least two studies. Estradiol, DHEA, and cortisol were the three most reported steroids in 15, 11, and 10 studies, respectively, and displayed alterations across various types of cancer, such as AC, PC, and LC. Moreover, 15 steroids displayed remarkably altered levels in four different types of cancer. A full list of the steroid biomarkers is shown in [Table S4](#app1-metabolites-09-00199){ref-type="app"}. From 55 steroids, we extracted the official steroid nomenclature using Human Metabolome Database version 4.0. Eventually, only 43 steroids with available HMDB ID were included in the pathway enrichment and network analysis. As a result, steroid compounds were listed in three significant pathways including Steroidogenesis, Androgen and Estrogen metabolism, and Androstenedione metabolism, with false discovery rates (FDR) of 0.00036, 0.047, and 0.07, respectively. More details about the pathway visualization and pathway characteristics can be found in [Figure 3](#metabolites-09-00199-f003){ref-type="fig"}a,b, [Figure S2](#app1-metabolites-09-00199){ref-type="app"}, and [Table S5](#app1-metabolites-09-00199){ref-type="app"}. In the network analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway mapping, steroid hormone biosynthesis was the most significant pathway, followed by well-known pathways including Metabolism of xenobiotics by cytochrome P450 and Drug metabolism-cytochrome P450 (data not shown). Network visualization is shown in [Figure 3](#metabolites-09-00199-f003){ref-type="fig"}c.

3. Discussion {#sec3-metabolites-09-00199}
=============

Metabolomics, an informatively rich platform, has emerged as an essential approach to discover novel biomarkers for the prevention, assessment, and management of cancers \[[@B69-metabolites-09-00199]\]. The ability to use metabolites as a non-invasive, promising tool for differentiating between cancerous and non-malignant conditions has been proven in previous systematic assessments \[[@B70-metabolites-09-00199],[@B71-metabolites-09-00199],[@B72-metabolites-09-00199]\]. Nevertheless, steroid characterization for clinical utility, in particular, remains a challenging area of metabolomics due to the existence of confounding factors and the requirement of strict protocols for proper sample treatment \[[@B73-metabolites-09-00199],[@B74-metabolites-09-00199],[@B75-metabolites-09-00199]\]. In the present work, we explored the accumulated evidence of the role of steroidomics in the prevention, assessment, and management of cancers. Our comprehensive evaluation showed that various steroid species are significantly associated with common cancers, particularly BC, EC, PC, and E/GC. Researchers have made attempts to overcome potential issues and achieved remarkable results in this sphere. However, some aspects remained inconsistent and required further improvement. Thus far, most of the included studies have focused on seeking potential steroids that showed a significant level of changes between two different conditions and had been biased in the risk prediction and diagnostic domain. Nevertheless, no study investigated a robust panel of steroid utilized for cancer risk assessment. Regarding diagnosis, researchers have recently conducted steroid profiling in order to discover steroid diagnostic biomarkers, which could aid in differentiating different diseases or between cancer patients and healthy people. For example, Kerkhofs et al. and Arlt et al. conducted a mass spectrometric steroid analysis and suggested a steroid panel to distinguish ACC and ACA with outstanding performances \[[@B20-metabolites-09-00199],[@B34-metabolites-09-00199]\]. In addition, Dai et al. discovered four potential steroids (cortisol, androstanediol, allo-tetrahydrocortisol, and epitestosterone), which were predictive of liver cirrhosis and early hepatocellular carcinoma with an AUC of 0.97 \[[@B31-metabolites-09-00199]\]. Similarly, a previous study showed that a biomarker panel demonstrated superior performance in cancer diagnosis and prognosis than a single biomarker \[[@B71-metabolites-09-00199]\]. In the current work, we proposed a list of commonly reported steroids that are associated with human cancer. These commonly reported steroids and their associated pathways could be utilized to establish an oncosteroid panel to improve prevention, assessment, and management of cancers.

Crucial information, such as age, gender, and follow-up, have not been well-described. It is notable that steroids are reported to demonstrate strong associations with these factors \[[@B73-metabolites-09-00199],[@B76-metabolites-09-00199]\]. Age is identified as a significant confounder, with considerable variability of plasma steroids resulting from wide age ranges. For example, DHEA, one of the most reported steroids among the included studies, has a robust negative correlation with age. Therefore, the lack of control for age, gender, and hormone use history could significantly affect the result and lead to misinterpretation \[[@B75-metabolites-09-00199],[@B77-metabolites-09-00199]\]. As mentioned earlier, steroid levels are gender and age-dependent and highly changeable due to differences in body mass index (BMI), sampling protocols, and history of hormone consumption, just to name a few \[[@B75-metabolites-09-00199],[@B76-metabolites-09-00199]\]. Therefore, these classic confounding factors should be recognized and well-controlled. Data stratification during sampling and data analysis based on gender, age range, and underlying diseases should be considered. A standardized procedure in terms of time, fasting, and type of biofluid containers could also minimize the variability of steroid levels. Moreover, follow-up should be considered in the study design whenever possible, especially in the diagnostic investigation. Samples should be stored at temperatures less than or equal to −20 °C, preferably at −80 °C for long-term storage \[[@B75-metabolites-09-00199]\]. Additionally, long-term, prospective follow-up populations, which may provide more useful information, have been generally lacking \[[@B78-metabolites-09-00199],[@B79-metabolites-09-00199]\]. The included studies mostly focused on cancer patients at late stages, but they may not be suitable for finding diagnostic biomarkers \[[@B80-metabolites-09-00199]\]. Finally, small sample size is also a common limitation, evidenced as only 20 studies had more than 100 samples in each group.

Qualitative and quantitative analyses of steroids demand proper and strict sample pretreatment processes \[[@B81-metabolites-09-00199]\]. Specifically, steroids can exist in conjugated and unconjugated forms in the human body. This leads to difficulties in setting up an efficient method for detecting steroidal compounds. Additionally, steroid levels greatly vary from serum, plasma, to urine \[[@B82-metabolites-09-00199]\]. Among commonly used biofluid samples, urine might be considered as the most non-invasive and intact sample compared to serum and plasma. In addition, urine profiling has been acknowledged as a crucial way to explore the disturbance of steroid synthesis \[[@B6-metabolites-09-00199]\]. However, high salt concentration might challenge the mass spectrometry assay when conducting urine profiling. Therefore, a pre-analytical step for separating the steroid from salt should be added before conducting the data acquisition. For example, the employment of solid-phase extraction can reduce the salt and concentrate the steroid \[[@B83-metabolites-09-00199]\]. In the case of serum and plasma profiling, the steroid level was strongly associated with diet and nutritional supply \[[@B75-metabolites-09-00199]\]. Therefore, fasting should be recommended when collecting the blood sample, where possible. Likewise, estrogens and testosterone were positively associated with BMI in postmenopausal women, with older postmenopausal women showing lower plasma levels of pregnenolone, DHEA, and DHEA-sulfate compared to younger women \[[@B73-metabolites-09-00199]\]. Consequently, several studies have reported interval references for individual steroid compounds to reduce the risk of misinterpretation and inappropriate clinical decisions \[[@B75-metabolites-09-00199],[@B84-metabolites-09-00199],[@B85-metabolites-09-00199]\]. Therefore, including standardized reference intervals in steroid studies should be considered to facilitate the translation of steroidomics to clinical practice \[[@B84-metabolites-09-00199]\].

Regarding the steroid profiling method, MS-based methods are the current state-of-the-art analytical platforms. These methods allow for high-throughput analysis and provide more specific qualitative and quantitative steroid metabolism. It should be noted that both GC-MS and LC-MS have their own advantages and disadvantages. Therefore, GC-MS and LC-MS should be complementary approaches to comprehensively detect steroid compounds in biological matrixes \[[@B86-metabolites-09-00199]\]. The statistical methods are also worth noting here; they have been discussed at length in a previous report by our group \[[@B70-metabolites-09-00199]\]. Currently, there have been no studies that have integrated multi-layer omics data, such as transcriptomics and proteomics, with steroidomics for cancer risk assessment, diagnosis, and prognosis. Moreover, the utility of statistical learning has not been thoroughly tested. These two complementary approaches should be considered as potential topics of research in the future. It should be noted that we, along with other researchers, have discussed and demonstrated benefits and pitfalls when applying statistical modeling in omics-related cancer research \[[@B87-metabolites-09-00199],[@B88-metabolites-09-00199],[@B89-metabolites-09-00199],[@B90-metabolites-09-00199],[@B91-metabolites-09-00199],[@B92-metabolites-09-00199]\]. Furthermore, there is a demand for standardized and calibrated analytical procedures and new analytical methods to characterize the steroid metabolome \[[@B84-metabolites-09-00199],[@B93-metabolites-09-00199],[@B94-metabolites-09-00199]\]. The integration of multidimensional omics data has achieved considerable success, and there is still room for improvement, especially in the construction of multi-omics prediction models \[[@B95-metabolites-09-00199],[@B96-metabolites-09-00199],[@B97-metabolites-09-00199]\].

Estrogens and estrogen metabolites were the central molecules in our network visualization. The network exhibited the connection between the estrogen and estrogen metabolites together with the associated enzymes. This observation is in accordance with the role of estrogens in cancer. Additionally, it suggests candidates for discovering new cancer therapeutics based on steroidogenic enzymes, which were recently investigated by others \[[@B98-metabolites-09-00199],[@B99-metabolites-09-00199]\]. Regarding other differentially expressed steroids, estradiol, DHEA, and cortisol were the most promising among steroid biomarkers. In particular, estradiol was associated with an increased risk of BC and EC, but with a decreased risk of E/GC \[[@B40-metabolites-09-00199],[@B42-metabolites-09-00199],[@B50-metabolites-09-00199]\]. Positive DHEA supplementation effects have been demonstrated in many disease stages \[[@B100-metabolites-09-00199]\]. In fact, DHEA has been shown to have a protective role against the proliferation and migration of breast and cervical cancers \[[@B101-metabolites-09-00199],[@B102-metabolites-09-00199]\]. Notably, Petrick and colleagues reported that the increase in DHEA plasma level significantly lowered the risk of esophageal/gastric cardia adenocarcinoma \[[@B40-metabolites-09-00199]\]. However, the mechanism of this beneficial effect is not well explored. High nocturnal cortisol level is correlated with the short-term survival of epithelial ovarian cancer patients \[[@B21-metabolites-09-00199]\]. In addition, other commonly reported steroids, such as testosterone, androstenedione, and DHEA-sulfate, were also observed to predict increased risk of breast cancer in women, with the elevation of premenopausal serum \[[@B103-metabolites-09-00199]\]. Generally, steroidogenesis has been extensively targeted by using inhibitors of steroidogenesis as therapeutic agents for cancer and other diseases \[[@B104-metabolites-09-00199],[@B105-metabolites-09-00199],[@B106-metabolites-09-00199]\]. Recently, the underlying mechanism of steroidogenesis was characterized in castration-resistant prostate cancer cell lines and tissues to provide better insights into steroid substrate utilization \[[@B107-metabolites-09-00199]\]. Moreover, differential gene expressions related to androgen and estrogen metabolism were explored between hereditary and sporadic prostate cancer \[[@B108-metabolites-09-00199]\]. In addition, estrogen and androgen blockade is a potential direction for personalized medicine in PC \[[@B109-metabolites-09-00199]\]. Androstenedione is a precursor of several steroids, such as testosterone, estradiol, and estrone. Therefore, catabolism of androstenedione might be linked to cancer-related androgen and estrone metabolism. Particularly, inhibiting the indirect conversion of androstenedione to dihydrotestosterone might help reduce the risk of PC \[[@B110-metabolites-09-00199]\].

4. Materials and Methods {#sec4-metabolites-09-00199}
========================

4.1. Systematic Literature Search Strategy {#sec4dot1-metabolites-09-00199}
------------------------------------------

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, [Table S6](#app1-metabolites-09-00199){ref-type="app"}) guidelines \[[@B111-metabolites-09-00199]\]. Systematic literature searches were performed on PubMed, Scopus, Embase, Web of Science Core Collection, Virtual Health Library (VHL), and Cochrane Controlled Register of Trials (CENTRAL) using the keywords: (steroid OR steroids) AND (tumor OR tumors OR tumour OR tumours OR tumorous OR tumourous OR malignancy OR cancer OR cancers OR cancerous OR carcinoma OR carcinoma OR adenoma OR neoplasm OR neoplasms OR neoplastic OR neoplasia) AND (diagnosis OR treatment OR therapy OR prognosis OR recurrence) AND ("metabolite profiling" OR "metabolite analysis" OR "metabolic profiling" OR "metabolic fingerprinting" OR "metabolic characterization" OR metabolite OR metabolome OR metabolomics OR metabolomic OR metabonomics OR metabonomic). The search results were first retrieved in March 2018 and updated regularly up to February 2019. This was supplemented with a manual search of bibliographic reference lists to include all relevant studies. There was no limit regarding the publication period.

4.2. Inclusion and Exclusion Criteria {#sec4dot2-metabolites-09-00199}
-------------------------------------

The search results were retrieved from the online databases and imported into Endnote X8 software. After the removal of duplicate records, the remaining records were imported to Rayyan, a tool for systematic reviews \[[@B112-metabolites-09-00199]\]. Next, we assessed the eligibility of each article by evaluating the title and abstract. The articles suited for the next step were selected if they met the following inclusion criteria: (1) reported at least one steroid molecule as a novel marker in patients with any cancers; (2) had comparison groups (cancer versus healthy/non-cancerous patients, before and after treatment); (3) used any high-throughput techniques including liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR); (4) performed statistical biomarker selection and evaluation (univariate, multivariate analysis, or machine learning) for the prediction, discrimination, and management of cancers from healthy and/or non-cancerous conditions. On the other hand, studies were excluded using the following criteria: (1) were in vitro cell culture or non-human studies; (2) had no suitable control groups; (3) were case reports and series, proposals, letters, conference abstracts, proposals, meeting records, or review articles; (4) overlapped population but had smaller sample size; (5) had no suitable analytical platforms; and (6) had no available abstract or full text. All references were independently assessed for inclusion or exclusion by at least two authors to avoid personal bias. The final included articles were then classified into four categories by the primary purpose of the study: risk prediction, diagnosis, prognosis, and therapy monitoring.

4.3. Data Extraction {#sec4dot3-metabolites-09-00199}
--------------------

The protocol of data extraction was according to that previously published by our group \[[@B70-metabolites-09-00199]\]. Briefly, the details on study design and population characteristics (year, sample size, age, gender, tumor type, tumor stage, reference diagnostic method, hormone therapy, and follow-up) were recorded from each eligible paper. Next, information relating to biospecimens (serum, plasma, urine), instrumental platforms such as GC-MS and LC-MS, fasting condition, sample preparation, sample storage, internal standard, analytical validation, compound identification method, and outlier detection was also recorded. Finally, details on the alterations of steroid compounds, statistical analyses, and if applicable, reference ranges of each article were noted. The data extractions were carried out independently by at least two review authors (NHA and SJK). Cholesterol and vitamin D were not considered as steroid molecules in this study.

4.4. Quality Assessment of Included Studies {#sec4dot4-metabolites-09-00199}
-------------------------------------------

QUADOMICS, an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment, was conducted to assess the quality of each included study \[[@B113-metabolites-09-00199]\]. The items 2 and 14, only applied for studies in phase 4, were not utilized in our study. In addition, the remaining 14 items were scored as "not available" if it could not be applied to a study. All study quality assessments were conducted independently by at least two authors (NHA and NPL), to avoid personal bias.

4.5. Steroid Functional Analysis and Pathway Visualization {#sec4dot5-metabolites-09-00199}
----------------------------------------------------------

The steroids reported in at least two studies were abstracted and included in the steroid metabolism pathway. We extracted the steroid nomenclature from Human Metabolome Database (HMDB) version 4.0 and then performed pathway enrichment analysis and network analysis using Metaboanalyst version 4.0 and OmicsNet, respectively \[[@B114-metabolites-09-00199],[@B115-metabolites-09-00199],[@B116-metabolites-09-00199]\]. The Small Molecular Pathway Database (SMPD) was used as the knowledgebase for conducting relevant enrichment analysis \[[@B117-metabolites-09-00199]\]. Other parameters were set as default. For accurate identification and classification of the steroids, we supplemented the nomenclature reported in the included studies by applying HMDB identification (HMDB ID) for the analysis. Compounds without HMDB IDs were excluded before the pathway and network analysis.

5. Conclusions {#sec5-metabolites-09-00199}
==============

Oncosteroidomics is a promising approach for clinical cancer research. Along with remarkable achievements at the initial stage, more efforts are needed to establish standardized methods to utilize the alterations of steroid metabolic networks for the prevention, assessment, and management of cancers. Rigorous study design, sampling procedure, analytical approaches, and statistical methods are required to provide more insightful applications of steroidomics in the future.
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metabolites-09-00199-t001_Table 1

###### 

Demographic characteristics of the included studies.

  Study and Year of Publication                                Sample Collection   Cohort Allocation                     Aim                  Patients                          Controls                      Follow-Up                                                                                                                                                                                                                   
  ------------------------------------------------------------ ------------------- ------------------------------------- -------------------- --------------------------------- ----------------------------- --------------------- ------------------------------------ ------------------------ ------------ ----- --------------------------------- -------- ------------- ------------------------------------------ ---------------- -----
  Schweitzer et al. (2018) \[[@B26-metabolites-09-00199]\]     Prospective         ENSAT                                 Diagnosis            ACC                               Pathologically confirmed      42                    M: 57; R: 20--80                     15/27                    I-V          NA    ACA                               Yes      66            M: 58; R: 21--81                           29/37            No
  Hines et al. (2017) \[[@B27-metabolites-09-00199]\]          Prospective         US                                    Diagnosis            ACC                               Pathologically confirmed      5                     NA                                   NA                       NA           No    H, ACA                            No       114, 61       M^1^: 42, 47; R^1^: 24--83, 25--83         48/66            NA
  Taylor et al. (2017) \[[@B28-metabolites-09-00199]\]         Prospective         UK                                    Diagnosis            ACC                               Pathologically confirmed      10                    M: 59; R: 47--69                     4/6                      NA           NA    ACA, PPC/PGL, NFAA                Yes      7, 15, 16     M: 68, 50, 62; R: 66--70, 44--66, 48--72   4/3; 8/7; 6/10   NA
  Qian et al. (2016) \[[@B29-metabolites-09-00199]\]           Prospective         China                                 Diagnosis            Primary LC                        AJCC                          66                    m: 57.5; SD: 9.6                     66/0                     I-II         No    CL, H                             No       59, 65        m: 50.6, 53.6; SD: 12.5, 15.4              59/0; 65/0       NA
  Velikanova et al. (2016) \[[@B30-metabolites-09-00199]\]     Prospective         Russia                                Diagnosis            ACC                               Pathologically confirmed      31                    M: 43; R: 33--57                     8/23                     NA           Yes   ACA-HNA, ACA-CS, H                No       52, 44, 25    M: 55, 48; R: 50--61, 21--54               17/35; 18/26     NA
  Kerkhofs et al. (2015) \[[@B20-metabolites-09-00199]\]       Retrospective       Netherland                            Diagnosis            ACC                               Pathologically confirmed^2^   27                    m: 57; SD: 14                        8/19                     II-IV        NA    ACA function, ACA non function    No       22, 85        m: 50, 58; SD: 12, 12                      6/16; 28/57      Yes
  Dai et al. (2014) \[[@B31-metabolites-09-00199]\]            Prospective         China                                 Diagnosis            HCC                               Pathologically confirmed      28                    NA                                   NA                       I^3^         NA    H, CL                             NA       21, 21        NA                                         NA               NA
  Perna et al. (2014) \[[@B32-metabolites-09-00199]\]          Prospective         UK                                    Diagnosis            ACC                               Pathologically confirmed      13                    m: 51.7; SD: 16.2                    4/9                      NA           NA    ACA-RML, ACA                      No       7, 11         m: 70.14, 54.3; SD: 8.84, 12.35            4/3; 2/9         NA
  Konieczna et al. (2013) \[[@B33-metabolites-09-00199]\]      Prospective         Poland                                Diagnosis            BlC, KC, PC, TC, others           Pathologically confirmed      58, 11, 9, 3, 11^4^   m: \>40                              46/12; 7/4; NA; NA; NA   NA           NA    H                                 No       100           m: \>40                                    61/39            NA
  Konieczna et al. (2013) \[[@B23-metabolites-09-00199]\]      Prospective         Poland                                Diagnosis            BlC, KC, PC, TC, others           NA                            47, 10, 7, 3, 10^4^   m: 65.00; SD: 10.40                  17/60                    NA           No    H                                 Yes      77            m: 46.97; SD: 18.51                        38/39            NA
  Arlt et al. (2011) \[[@B34-metabolites-09-00199]\]           Retrospective       ENSAT                                 Diagnosis            ACC                               Pathologically confirmed      45                    M: 55; R: 20--80                     24/21                    NA           No    ACA, H                            NA       102, 88       M: 60; R: 19--84; 18--60                   39/63; 26/62     Yes
  Bufa et al. (2010) \[[@B35-metabolites-09-00199]\]           Prospective         Hungary                               Diagnosis            AE                                NA                            13                    m: 67.9; SD: 8.5                     0/13                     NA           NA    H                                 Yes      10            m: 58.7; SD: 6.2                           0/10             NA
  Bufa et al. (2008) \[[@B36-metabolites-09-00199]\]           Prospective         Hungary                               Diagnosis            EOC                               NA                            15                    m: 60.4; SD: 5.1                     0/15                     NA           NA    H                                 Yes      10            m: 58.7; SD: 6.2                           0/10             NA
  Drafta et al. (1982) \[[@B37-metabolites-09-00199]\]         Prospective         Romania                               Diagnosis            PC                                UICC 1974 and VACRG           32                    m: 67; R: 51--79                     32/0                     I-IV         NA    BPH, H                            Yes^5^   54, 63        m: 68, 66; R: 50--78, 50--79               54/0; 63/0       NA
  Trabert et al. (2019) \[[@B38-metabolites-09-00199]\]        Retrospective       WHI-OS                                Risk prediction      OC                                NA                            169                   m: 64.1; SD: 7.2                     0/169                    NA           No    H                                 Yes      410           m: 64.3; SD: 7.2                           0/410            Yes
  Petrick et al. (2018) \[[@B39-metabolites-09-00199]\]        Retrospective       Northern Ireland, Ireland             Risk prediction      EA                                Pathologically confirmed      172                   m: 64.3; SD: 10.9                    172/0                    NA           No    H                                 Yes      185           m: 63.5; SD: 12.6                          185/0            NA
  Petrick et al. (2018) \[[@B40-metabolites-09-00199]\]        Retrospective       PLCO, ATBC, CPS-II nutrition cohort   Risk prediction      EA/GCA                            NA                            259                   m: 62.0; SD: 6.6                     259/0                    NA           No    H                                 Yes      259           m: 61.0; SD: 6.6                           259/0            NA
  Sampson et al. (2017) \[[@B41-metabolites-09-00199]\]        Retrospective       PLCO, US, B-FIT, SWHS                 Risk prediction      BC                                NA                            1298                  NA                                   0/1298                   NA           No    H                                 Yes      1524          NA                                         0/1524           Yes
  Brinton et al. (2016) \[[@B42-metabolites-09-00199]\]        Retrospective       WHI-OS                                Risk prediction      EC                                NA                            313                   m: 64.5; SD: 7.0                     0/313                    NA           No    H                                 Yes      354           m: 64.0; SD: 7.0                           0/354            Yes
  Moore et al. (2016) \[[@B43-metabolites-09-00199]\]          Retrospective       China                                 Risk prediction      BC                                NA                            399                   NA                                   0/399                    NA           No    H                                 Yes      399           NA                                         0/399            Yes
  Trabert et al. (2016) \[[@B44-metabolites-09-00199]\]        Retrospective       WHI-OS                                Risk prediction      OC                                NA                            169                   m: 64.1; SD: 7.2                     0/169                    NA           No    H                                 Yes      412           m: 64.3; SD: 7.2                           0/412            Yes
  Dallal et al. (2016) \[[@B45-metabolites-09-00199]\]         Retrospective       B-FIT                                 Risk prediction      EC                                NA                            66                    m: 67.5; SD: 5.6                     0/66                     NA           No    H                                 No       346           m: 67.0; SD: 6.2                           0/346            Yes
  \-                                                           Retrospective       B-FIT                                 Risk prediction      OC                                NA                            67                    m: 68.5; SD: 5.7                     0/67                     NA           No    H                                 No       416           m: 67.0; SD: 6.3                           0/416            Yes
  Schairer et al. (2015) \[[@B46-metabolites-09-00199]\]       Retrospective       PLCO                                  Risk prediction      BC (estrogen receptor positive)   NA                            193                   R: 55--74                            0/193                    NA           No    H                                 Yes      268           NA                                         0/268            Yes
  Black et al. (2014) \[[@B47-metabolites-09-00199]\]          Retrospective       PLCO                                  Risk prediction      PC                                NA                            195                   R: 55--70                            195/0                    III-IV       No    H                                 Yes      195           R: 55--70                                  195/0            Yes
  Falk et al. (2013) \[[@B48-metabolites-09-00199]\]           Retrospective       US                                    Risk prediction      BC                                NA                            215                   NA                                   0/215                    NA           No    H                                 Yes      215           NA                                         0/215            Yes
  Dallal et al. (2013) \[[@B49-metabolites-09-00199]\]         Retrospective       B-FIT                                 Risk prediction      BC                                NA                            407                   m: 67.2; SD: 5.7                     0/407                    NA           No    H                                 No       496           m: 67.3; SD: 6.2                           0/496            Yes
  Fuhrman et al. (2012) \[[@B50-metabolites-09-00199]\]        Retrospective       PLCO                                  Risk prediction      BC                                NA                            277                   R: 55--74                            0/277                    NA           No    H                                 No       423           R: 55--74                                  0/423            Yes
  Audet-Walsh et al. (2010) \[[@B51-metabolites-09-00199]\]    Retrospective       Canada                                Risk prediction      EC                                NA                            126                   m: 64.8; SD: 9.1                     0/126                    I-IV         No    H                                 No       110           m: 58.3; SD: 5.6                           0/110            NA
  Yang et al. (2009) \[[@B52-metabolites-09-00199]\]           Prospective         US                                    Risk prediction      PC                                NA                            14                    m: 63.6; R: 50--83                   14/0                     NA           NA    H                                 No       125           m: 64.8; R: 45--78                         125/0            NA
  Lévesque et al. (2019) \[[@B53-metabolites-09-00199]\]       Retrospective       Canada                                Prognosis            PC                                NA                            1776^6^               m: 62.7; SD: 6.4                     1776/0                   I-IV         No    PC                                Yes      1776^6^       m: 62.7; SD: 6.4                           1776/0           Yes
  Audet-Delage et al. (2018) \[[@B54-metabolites-09-00199]\]   Prospective         Canada                                Prognosis            EC                                Pathologically confirmed      246                   m: 65.1; SD: 8.9                     0/246                    I-IV         No    EC^7^, H                          Yes      246, 110      m: 65.1, 58.3; SD: 8.9, 5.6                0/246; 0/110     Yes
  Plenis et al. (2013) \[[@B55-metabolites-09-00199]\]         Prospective         Poland                                Prognosis            NET                               NA                            19^8^                 m: 54.6; SD: 11.8                    10/9                     NA           NA    H                                 Yes      20            m: 47.3; SD: 12.5                          10/10            NA
  Lévesque et al. (2013) \[[@B56-metabolites-09-00199]\]       Prospective         Canada                                Prognosis            PC                                Pathologically confirmed      526^9^                m: 63.3; SD: 6.8                     NA                       NA           No    NA                                NA       NA            NA                                         NA               NA
  Thomas et al. (1982) \[[@B57-metabolites-09-00199]\]         Prospective         UK                                    Prognosis            BC^10^                            Pathologically confirmed      109                   NA                                   0/109                    I-II         NA    BC^11^                            NA       109           NA                                         0/109            Yes
  Zang el at. (2014) \[[@B58-metabolites-09-00199]\]           Prospective         US                                    Diagnosis            PC                                NA                            64                    m: 59; R: 49--65                     64/0                     NA           No    H                                 Yes      50            m: 50; R: 45--76                           50/0             NA
  Song et al. (2012) \[[@B59-metabolites-09-00199]\]           Prospective         China                                 Diagnosis            GC                                Pathologically confirmed      30                    M: 63; R: 39-88                      15/15                    I-IV         No    H                                 Yes      30            M: 62; R: 42--82                           15/15            No
  Moore et al. (2018) \[[@B60-metabolites-09-00199]\]          Retrospective       PLCO                                  Risk prediction      BC                                NA                            621                   R: 55--74                            0/621                    NA           No    H                                 Yes      621           R: 55--74                                  0/621            Yes
  Huang et al. (2017) \[[@B61-metabolites-09-00199]\]          Retrospective       Finland                               Risk prediction      PC                                NA                            137                   m: 59.8, 58, 60.9                    137/0                    II-IV        NA    H                                 Yes      200           m: 59.3                                    200/0            NA
  Mondul et al. (2015) \[[@B62-metabolites-09-00199]\]         Retrospective       ATBC                                  Risk prediction      PC                                AJCC                          200                   m: 59.4                              200/0                    III-IV       No    H                                 Yes      200           m: 59.3                                    200/0            Yes
  Huang et al. (2018) \[[@B63-metabolites-09-00199]\]          Retrospective       Finland                               Prognosis            3rd tertile of PC                 AJCC                          197^6,\ 12^           m: 69; R: 55--86                     197/0                    I-IV         NA    1st and 2nd tertile of PC         No       197^6,\ 12^   m: 69; R: 55--86                           197/0            Yes
  Ye et al. (2014) \[[@B64-metabolites-09-00199]\]             Prospective         China                                 Prognosis            OSCC (S)                          UICC 2002                     11                    M: 52; R: 35--74                     7/4                      III-IVA      No    OSCC (NS)                         Yes      21            M: 53; R: 45--71                           15/6             NA
  Zhou et al. (2014) \[[@B65-metabolites-09-00199]\]           Prospective         China                                 Prognosis            HCC                               6^th^ TNM                     22^13^                m: 47; SD: 12                        19/3                     I-IIIB^14^   NA    HCC                               Yes      18            m: 45; SD: 11                              15/3             Yes
  Miller et al. (2015) \[[@B66-metabolites-09-00199]\]         Prospective         US                                    Therapy monitoring   BC after limonene intervention    Pathologically confirmed      40^6^                 M: 58.5; IQR: 18.5                   0/40                     IS-T1        NA    BC before limonene intervention   Yes      40^6^         M: 58.5, IQR: 18.5                         0/40             NA
  Ghataore et al. (2012) \[[@B67-metabolites-09-00199]\]       Prospective         France                                Therapy monitoring   ACC                               Pathologically confirmed      17                    M^15^: 50/47; R^15^: 26--66/20--76   6/11^16^                 NA           Yes   H                                 No       40            M^15^: 31/29; R^15^: 22--49/20--59         20/20            Yes
  Saylor et al. (2012) \[[@B68-metabolites-09-00199]\]         Prospective         US                                    Therapy monitoring   PC after ADT                      NA                            36                    NA                                   36/0                     NA           No    PC before ADT                     Yes      36            NA                                         36/0             Yes

AJCC: American Joint Committee on Cancer; ACC: Adrenocortical carcinoma; ACA: Adrenocortical adenoma; ADT: Androgen deprivation therapy; AE: Adenocarcinoma endometrii; ATBC: The Alpha-Tocopherol, Beta-Carotene Cancer Prevention; ACA-CS: Adrenocortical adenoma with Cushing's syndrome; ACA-HNA: Adrenocortical adenoma hormonally non-active adenomas; ACC-RML: Adrenocortical adenoma with regression and myelolipomatous changes; BC: Breast Cancer; BPH: Benign protatic hyperplasia; BlC: Bladder cancer; B-FIT: The Breast and Bone Follow-up to the Fracture Intervention Trial; CL: Cirrhotic liver; CSP II: Cancer Prevention Study II; EA: Esophageal adenocarcinoma; EOC: Epithelial ovarian cancer; ENSAT: European Network for the Study of Adrenal Tumors; EC: Endometrial cancer; GC: Gastric cancer; GAC: Gastric cardia adenocarcinoma; H: Health; HCC: Hepatocellular carcinoma; IQR: Interquartile range; KC: Kidney cancer; LC: Liver cancer; M: Median; m: Mean; NET: Neuroendocrine Tumor; NFAA: Nonfunctioning adrenal adenoma; NA: Not available; OSCC (S): Oral squamous cell carcinoma patient with significant chemotherapy efficacy; OSCC (NS): Oral squamous cell carcinoma patient with nonsignificant chemotherapy efficacy; PC: Prostate cancer; PCC/PGL: Phaeochromocytoma/paraganglioma; PLCO: The Prostate, Lung, Colorectal and Ovarian; OC: Ovarian cancer; R: Range; SD: Standard deviation; SWHS: The Shanghai Women's Health Study; TC: Testis cancer; TNM: TNM Classification of Malignant Tumors; UICC: Union for International Cancer Control; VACURG: Veterans Administration Cooperative Urologic Research Group; WHI-OS: Women's Health Initiative Observational Study; 1: From healthy male and female individuals; 2: 25/27 patients; 3: 24/28 patients; 4: Patients in other urogenital tract cancers; 5: PC match with the control group; 6: Total population; 7: Sample taken after surgery; 8: Patients treated with somatostatin analogs; 9: Postmenopausal population; 10: BC with lower androsterone and aetiocholonolone levels than medium; 11: BC with higher androsterone and aetiocholonolone levels than medium; 12: 92 prostate cancer deaths during the period of follow-up; 13: Early intrahepatic recurrence; 14: Stage for both groups; 15: Value of male/female; 16: Six of premenopausal age.
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###### 

Potential steroid biomarkers ^\*^ reported in at least four studies.

  Steroid Compound                  Biomarker Function in Cancer   Reference                                        
  --------------------------------- ------------------------------ ----------- --- --- ---- --- --- --- --- --- --- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Estradiol                         ↑                              ↑           ↑       ↑    ↑               ↑   ↓   \[[@B26-metabolites-09-00199],[@B29-metabolites-09-00199],[@B37-metabolites-09-00199],[@B39-metabolites-09-00199],[@B40-metabolites-09-00199],[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B45-metabolites-09-00199],[@B46-metabolites-09-00199],[@B48-metabolites-09-00199],[@B49-metabolites-09-00199],[@B50-metabolites-09-00199],[@B54-metabolites-09-00199]\]
  Dehydroepiandrosterone            ↑                              ↑                   ↑↓   ↑               ↑   ↓   \[[@B26-metabolites-09-00199],[@B27-metabolites-09-00199],[@B30-metabolites-09-00199],[@B32-metabolites-09-00199],[@B36-metabolites-09-00199],[@B39-metabolites-09-00199],[@B40-metabolites-09-00199],[@B51-metabolites-09-00199],[@B53-metabolites-09-00199],[@B54-metabolites-09-00199],[@B56-metabolites-09-00199]\]
  Cortisol                          ↑                              ↑               ↑        ↓           →           \[[@B23-metabolites-09-00199],[@B26-metabolites-09-00199],[@B27-metabolites-09-00199],[@B28-metabolites-09-00199],[@B30-metabolites-09-00199],[@B31-metabolites-09-00199],[@B33-metabolites-09-00199],[@B37-metabolites-09-00199],[@B55-metabolites-09-00199],[@B68-metabolites-09-00199]\]
  Pregnanetriol                     ↑                              ↑                   ↑                    ↑       \[[@B20-metabolites-09-00199],[@B27-metabolites-09-00199],[@B30-metabolites-09-00199],[@B34-metabolites-09-00199],[@B35-metabolites-09-00199],[@B36-metabolites-09-00199]\]
  Testosterone                                                     ↑               ↓   ↑    ↓   ↑       →       ↓   \[[@B23-metabolites-09-00199],[@B29-metabolites-09-00199],[@B33-metabolites-09-00199],[@B37-metabolites-09-00199],[@B39-metabolites-09-00199],[@B51-metabolites-09-00199],[@B54-metabolites-09-00199],[@B55-metabolites-09-00199],[@B56-metabolites-09-00199]\]
  Estrone                                                          ↑           ↑       ↑↓   ↑               ↑   ↓   \[[@B29-metabolites-09-00199],[@B37-metabolites-09-00199],[@B39-metabolites-09-00199],[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B48-metabolites-09-00199],[@B51-metabolites-09-00199],[@B54-metabolites-09-00199]\]
  2-methoxyestrone                                                 ↑           ↑       ↑                    ↑       \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B47-metabolites-09-00199],[@B49-metabolites-09-00199]\]
  Pregnanediol                      ↑                                                                       ↑       \[[@B20-metabolites-09-00199],[@B27-metabolites-09-00199],[@B30-metabolites-09-00199],[@B32-metabolites-09-00199],[@B34-metabolites-09-00199],[@B36-metabolites-09-00199]\]
  Androsterone                      ↑                              ↑           ↓       ↑↓                       ↓   \[[@B20-metabolites-09-00199],[@B35-metabolites-09-00199],[@B39-metabolites-09-00199],[@B54-metabolites-09-00199],[@B56-metabolites-09-00199],[@B57-metabolites-09-00199]\]
  Dehydroepiandrosterone sulfate    ↑                              ↑                   ↑    ↑                       \[[@B26-metabolites-09-00199],[@B28-metabolites-09-00199],[@B51-metabolites-09-00199],[@B53-metabolites-09-00199],[@B54-metabolites-09-00199],[@B65-metabolites-09-00199],[@B68-metabolites-09-00199]\]
  2-hydroxyestrone                                                 ↑           ↑       ↑                    ↑       \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B45-metabolites-09-00199],[@B48-metabolites-09-00199]\]
  Estriol                                                                      ↑       ↑                    ↑       \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B48-metabolites-09-00199],[@B49-metabolites-09-00199],[@B54-metabolites-09-00199]\]
  16-epiestriol                                                                ↑       ↑                    ↑       \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B48-metabolites-09-00199],[@B49-metabolites-09-00199]\]
  16α-hydroxyestrone                                                           ↑       ↑                    ↑       \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B45-metabolites-09-00199]\]
  Etiocholanolone                   ↑                                          ↑       ↑                            \[[@B20-metabolites-09-00199],[@B27-metabolites-09-00199],[@B30-metabolites-09-00199],[@B34-metabolites-09-00199],[@B35-metabolites-09-00199],[@B57-metabolites-09-00199]\]
  Androstenedione                   ↑                              ↑                   ↑                            \[[@B26-metabolites-09-00199],[@B28-metabolites-09-00199],[@B51-metabolites-09-00199],[@B54-metabolites-09-00199],[@B58-metabolites-09-00199]\]
  Dihydrotestosterone               ↑                              ↑                   ↑                        ↓   \[[@B26-metabolites-09-00199],[@B39-metabolites-09-00199],[@B51-metabolites-09-00199],[@B54-metabolites-09-00199],[@B56-metabolites-09-00199]\]
  16-ketoestradiol                                                             ↑       ↑                    ↑       \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B49-metabolites-09-00199]\]
  Tetrahydrodeoxycortisol           ↑                                                                               \[[@B20-metabolites-09-00199],[@B27-metabolites-09-00199],[@B30-metabolites-09-00199],[@B34-metabolites-09-00199]\]
  Cortisone                         ↑                                              ↑                    →           \[[@B23-metabolites-09-00199],[@B27-metabolites-09-00199],[@B30-metabolites-09-00199],[@B33-metabolites-09-00199],[@B55-metabolites-09-00199]\]
  Progesterone                      ↑                              ↓               ↓            ↓   ↓   →           \[[@B23-metabolites-09-00199],[@B26-metabolites-09-00199],[@B33-metabolites-09-00199],[@B55-metabolites-09-00199]\]
  Androstenediol                                                                       ↑                        ↓   \[[@B39-metabolites-09-00199],[@B51-metabolites-09-00199],[@B53-metabolites-09-00199],[@B54-metabolites-09-00199]\]
  2-hydroxyestrone-3-methyl ether                                              ↑       ↑                            \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B48-metabolites-09-00199]\]
  4-hydroxyestrone                                                             ↑       ↑                    ↑       \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B44-metabolites-09-00199],[@B45-metabolites-09-00199]\]
  4-methoxyestrone                                                 ↑                   ↑                    ↑       \[[@B42-metabolites-09-00199],[@B44-metabolites-09-00199],[@B47-metabolites-09-00199],[@B54-metabolites-09-00199]\]
  17-epiestriol                                                                ↑       ↑                            \[[@B41-metabolites-09-00199],[@B42-metabolites-09-00199],[@B43-metabolites-09-00199],[@B45-metabolites-09-00199],[@B49-metabolites-09-00199]\]

↑: Significant increase in cancer or more aggressive group; ↓: Significant decrease in cancer or more aggressive group; →: Significant differences (not shown if increased or decreased); \* The order of steroids was sorted based on number of papers recorded; AC: Adrenal cancer; PC: Prostate cancer; BC: Breast cancer; BlC: Bladder cancer; EC: Endometrial cancer; LC: Liver cancer; KC: Kidney cancer; TC: Testicle cancer; NET: Neuroendocrine Tumor; OC: Ovarian cancer; E/GC: Esophagus/Gastric cancer.

[^1]: These authors contributed equally to this work.
